

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

PerCP/Cyanine5.5 anti-mouse/human CD44

RRID:AB_2076206

Type: Antibody

Proper Citation

BioLegend Cat# 103031, RRID:AB_2076206

Antibody Information

URL: http://antibodyregistry.org/AB_2076206

Proper Citation: BioLegend Cat# 103031, RRID:AB_2076206

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_2076206

Vendor: BioLegend

Catalog Number: 103031

Alternative Catalog Numbers: 103032

Record Creation Time: 20250820T025913+0000

Record Last Update: 20250820T150229+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-mouse/human CD44.

No alerts have been found for PerCP/Cyanine5.5 anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. *Immunity*, 59(1), 161.

Smyth DJ, et al. (2025) Vaccination against helminth IL-33 modulators permits immune-mediated parasite ejection. *Cell reports*, 44(5), 115721.

Benamar M, et al. (2025) Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. *Immunity*, 58(11), 2753.

León-Letelier RA, et al. (2025) Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells. *Vaccines*, 13(6).

Yin Y, et al. (2025) Activated T cells degrade extracellular proteins to enhance effector functions. *Cell reports*, 45(1), 116797.

Wallace RP, et al. (2024) Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics. *Cell reports. Medicine*, 5(1), 101345.

Fontana P, et al. (2024) Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity. *Cell*, 187(22), 6165.

Graziano V, et al. (2023) Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. *Journal for immunotherapy of cancer*, 11(8).

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- γ axis. *Cell reports*, 42(8), 112944.

Si Y, et al. (2023) Lung cDC1 and cDC2 dendritic cells priming naive CD8+ T cells in situ prior to migration to draining lymph nodes. *Cell reports*, 42(10), 113299.

Webb ER, et al. (2022) Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma.

iScience, 25(9), 104995.

Chen W, et al. (2022) Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8⁺ T cell exhaustion and curtails anti-PD-1 efficacy. *Cell reports*, 41(7), 111647.

Ringel AE, et al. (2020) Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. *Cell*, 183(7), 1848.

Benci JL, et al. (2019) Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. *Cell*, 178(4), 933.

Amir M, et al. (2018) REV-ERB α Regulates TH17 Cell Development and Autoimmunity. *Cell reports*, 25(13), 3733.

Nabet BY, et al. (2017) Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer. *Cell*, 170(2), 352.

Benci JL, et al. (2016) Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell*, 167(6), 1540.